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Graves' Disease Following the Occurrence of Hypothyroidism
A. R. Guansing, MD,* D. D. Klink, MD,* N. Engbring, MD,** Y. Leung, MD,***
J. chakravarty, MD,*** and S. Wilson, MD**

Three patients with hypothyroidism of 15-48 months' duration developed Graves' disease while on thyroid hormone
replacement therapy. In one patient, the hyperthyrold
phase was preceded by ophthalmopathy and nonsuppresslble 24-hour radioactive iodine uptake (RAIU). Eventually,
all had hyperthyrold findings with elevated thyroid hormone levels, high 24-hour RAIU, and a diffuse uniform
uptake of RAI by the enlarged thyroid. All subjects had

negative antithyroglobulin
and antimicrosomal
antibody
titers. Two had demonstrable long-acting thyroid stimulator
(LATS) in their sera. All three were followed for 5-36
months while on propylthiouracil therapy prior to surgery
or RAI administration. Both LATS-positive patients underwent bilateral subtotal thyroidectomy. Classical changes of
Graves' disease were found on histopathological examination of resected tissues.

T h e occurrence of Graves' disease after a period of hypothyroidism is an unusual phenomenon. Since 1930, the
English literature describes almost 80 patientswith Graves'
disease following use of thyroid extract or synthetic thyroid
hormone (1-11). However, only 24 had substantial evidence that suggested prior hypothyroidism, and ofthe 24,
14 had well-documented evidence to support the diagnosis
(6-16). In the majority of patients, obesity was the primary
indication for thyroid hormone therapy (1-3). Attention was
therefore focused on the possible association of prior thyroid extract therapy and the subsequent development of
"exophthalmic goiter" with hyperthyroidism. Not until
1967 were autoimmune mechanisms considered a possible
cause of hyperthyroidism in this subset of patients (4). This
report deals with three cases of Graves' disease following
unequivocal hypothyroidism which can be best explained
on the basis of autoimmune mechanisms.

Patients and Methods
Three patients with a history of hypothyroidism were referred to The Medical College of Wisconsin for manifestations of hyperthyroidism while they were on thyroid
hormone replacement therapy.
The clinical history and physical findings during the disease period were reviewed, as well as the laboratory
procedures performed before and during thyroid hormone
therapy. The diagnosis of hypothyroidism was verified in all
three patients with the determination of serum proteinbound iodine (PBI) and/or serum thyroxine (T4) levels
together with Ts-resin uptake (T3RU). Initial 24-hour radioactive iodine uptake (RAIU) tests were performed on
two patients before therapy.
All three patients were seen one to three months after their
thyroid hormone medication had been discontinued. A
complete history and thorough physical examination were
made on each patient and appropriate thyroid function
studies were performed. Serum triiodothyronine (T3) and T4
were measured by standard radioimmunoassay procedures
(17,18). Serum T3RU values were determined with a commercially available kit (Abbott Laboratories, North Chicago, IL) except w h e n otherwise i n d i c a t e d . The free
thyroxine index (FTI) was calculated for each of the subjects (19). Radioimmunoassay for serum TSH was carried
outwith commercially available materials (Beckman Company, Fullerton, CA). Thyroid antibodies were checked with
the hemagglutination techniques for antithyroglobulin and
antimicrosomal antibody determinations (20,21). An im-
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munofluorescent antibody technique was also employed
for patients 2 and 3 (22). Werner's suppression test was
used in patient 3, with 50% suppressibility of RAIU as the
minimal criterion for response (23). The presence of a longacting thyroid stimulator (LATS) in serum was verified by
Bioscience Laboratories (Van Nuys, CA) using the
McKenzie method (24). RAI uptake and scans were performed for all three subjects.

peared until 48 months later w h e n he developed
hyperthyroidism.
Patient 3 presented with mild symptoms of cold intolerance
and tiredness at age 54 but few physical findings. He did
not have thyromegaly. He was treated with 0.2 mg of Lthyroxine until 15 months later w h e n he developed
gynecomastia, exophthalmos, and diplopia without signs
and symptoms of hyperthyroidism. The L-thyroxine was
promptly discontinued.

Propranolol, a beta-adrenergic block agent, was given for
symptomatic relief, and propylthiouracil (PTU) was administered in appropriate doses to the patients over a period of
5-26 months. Subsequently, bilateral subtotal thyroidectomy was performed on two patients, and RAI therapy was
instituted on the third.

None of the patients were taking any iodide preparation.
Family histories revealed that the mother of the first patient
had required thyroid medications for approximately three
months during her mid-thirties. She is now euthryoid and
without any evidence of goiter. Patient 2 did not have a
family history significantly related to hyperthyroidism. The
father of patient 3 had undergone surgery for a goiter which
was benign.

Results
Hypothyroid phase

Hyperthyrold phase

Table 1 summarizes some of the clinical and laboratory
features of the three patients.

Table 11 illustrates the salient clinical and laboratory findings at the time hyperthyroidism developed, and Table III
shows other laboratory procedures performed during the
initial phase.

Patient 1 was found to have an "adolescent goiter" 14
months before clinical hypothyroidism developed. Her
serum PBI atthe time was 6.2 /x,g/dl (n =2.5-6.7 /u-g/dl), and
the T3RU was 29.1% (n =25-35%). Then at age 11 she
developed progressive weight gain, cold intolerance, sluggishness, dry skin, coarse scalp hair, puffy eyelids, and
persistence of thyromegaly. Her serum PBI decreased to 1.3
ju,g/dl with a T3RU of 20%. When desiccated thyroid was
started at a maintenance dose of 3 gr/day, all of her
symptoms improved, she gained weight, and her goiter
disappeared. Menarche began at age 12 with normal menstrual cycles. The desiccated thyroid was gradually decreased and finally discontinued after 35 months when she
developed signs of hyperthyroidism.

Patient 1 developed a progressive weight loss of 11 pounds
in two months with generalized weakness, increased nervousness, irritability, and heat intolerance. She was normotensive with a tachycardia of 90/minute. There was lidlag and diffuse thyromegaly with soft to firm consistency.
She had an estimated weight of 60 gm. A bruit was present
over the goiter. Her skin was moist, and fine tremors of both
hands were observed. The remainder of her physical examination was within normal limits. Results o f t h e laboratory
studies are shown in Table 11. Over the next 35 months her
serum TSH levels varied from 4.1 p.U/m\ to 10.9 jU,U/ml,
depending on the amount of PTU medication she was
taking.

Patient 2 presented with signs and symptoms of hypothyroidism, but no thyromegaly was found. On 2-3 gr of
desiccated thyroid daily, all signs and symptoms disap-

Patient 2 presented with a progressive weight loss of 30
pounds and severe weakness ofthe lower limbs. On physi-

TABLEI
Clinical Findings During the Hypothyroid Phase

Patient

Age of onset
(years)

Sex

1

11

Presenting symptoms
"Adolescent" goiter preceded
hypothyroidism x 14 months;
weight gain; cold intolerance

PBI
(2.5-6.7/ig/dl)

T4
(5.5-14^g/dl)

T3RU

24-hour RAI
uptake (10-35%)

1.3

—

20%
(25-35%)

1%
4%

2

M

12

Fatigue; cold intolerance;
puffy eyes

1,5

1.0

—

3

M

54

Cold intolerance

—

1.8

35%
(43-60%)
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TABLE II
Clinical and Laboratory Features During the Hyperthyrold Phase

Patient

Sex

Age of onset
(years)

F

14

M

16

M

56

Serum T4
(4-11.5Mg/dl)

Serum T
(70-215 ng/ml

T3RU
(25-35%)

TSH
(<10/xU/ml)

Diffuse goiter; tremors;
tachycardia

19.4

380

42%

2.2

Diffuse goiter; tachycardia; severe myopathy

27.4

570

44%

6.4

41%

3.8

Salient findings

Mild thyromegaly
exophthalmos and diplopia;
gynecomastia

14.5

request of patient 1 and her family, this was done three
years later. At surgery, 170 gm of thyroid tissue was resected; on histological examination, it showed pseudopapillary proliferation of tall columnar cells with some
islands of lymphoid nodules scattered throughout. Actual
lymphocytic infiltration was not observed. Patient 2 had a
bilateral subtotal thyroidectomy after 12 months of PTU
therapy. Histological findings were almost identical except
for the weight of the tissue removed (160 gm). Patient 3
received 10 mCi of RAI as ablative therapy when hyperthyroidism recurred at six months, after PTU had been
discontinued for 30 days. All three patients were euthyroid
on L-T4 replacement therapy 26-72 months after these
procedures.

cal examination, he was tachycardic at 110/minute, with a
normal blood pressure (124/80 mmHg). Lid-lag was bilateral. A diffuse goiter was found. The remainder of the
physical findings were within normal limits except for
severe pelvic girdle muscle weakness with lesser involvement of the distal musculature. Electromyography showed
low voltage with polyphasic potentials consistent with
myopathy. Cerebrospinal fluid findings were normal. Table
II shows the results of the laboratory findings. At the end of
10 months his serum TSH decreased to 2.8 ptU/ml together
with a return to normal of both serum T4 and T3. Skull xrays showed a normal sella turcica.
Patient 3 initially presented with exophthalmos, diplopia,
and unilateral gynecomastia w i t h o u t galactorrhea.
Werner's suppression test showed an initial 24-hour RAIU
of 30% and a subsequent value of 38% at the end of 10
days of triiodothyronine, 75 /Ag/day in three divided doses
(Table 111). One month later he developed manifestations
of hyperthyroidism. He lost 12 pounds and was found to
be mildly tachycardic (HR=90/minute). Eye findings included marked limitation of upward gaze and limited
lateral gaze bilaterally. Hertel exophthalmometry at base
100 was 23 mm O D and 22 mm OS. A small goiter was
found. Except for unilateral gynecomastia, physical findings were otherwise unremarkable. Both testes were of
normal size. Laboratory studies showed elevation of serum
T4 to 14.5 Mg/dl, T3RU at 4 1 % , and the FTI to 6.9. Three
months later, while on PTU, he became euthyroid with
both serum T4 and T3RU decreasing to 5.2 p.g/d\ and 25%,
respectively, and serum TSH remaining normal at
3.8 /xU/ml. On the fourth month his TSH increased to
18 ptU/ml. PTU was discontinued. Excision of the gynecomastia revealed normal breast tissue, and skull x-rays
showed a normal sella turcica.

Discussion
Graves' disease following hypothyroidism is an unusual
sequence of events that is not well recognized. In these
three patients the clinical history and laboratory findings
indicated hypothyroidism preceding hyperthyroidism.

TABLE ill
Other Laboratory Findings During Hyperthyroidism
24-hour RAI uptake
Thyroid scan

Patient LATS Anti-Tg Anti-M
(10-35%)
1

(+)

(-)

(-)

51%

Enlarged with
uniform uptake

2

(+)

(-)

(-)

79%

Enlarged with
uniform uptake

3

NO

(-)

(-)

30%
38%*

"Normal" size
uniform uptake

* After 10 days of T3, 75 fig/day

As shown in Table IV, appropriate doses of propranolol
and/or PTU were administered to the three patients for a
period of 5-36 months. Bilateral subtotal thyroidectomy
was recommended to patients 1 and 2 (who were still in
their teens) at the end of one year of PTU therapy. At the

ND = not done
LATS = long-acting thyroid stimulator
Anti-Tg = antithyroglobulin antibody
Anti-M = antimicrosomal thyroid antibody
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TABLE IV
Treatment Procedures During Thyrotoxic Phase

Patient

First treatment

Duration
(months)

Second treatment

Findings*

1

PTU, 100 mg qid; propranolol,
20 mg qid

36

Bilateral subtotal
thyroidectomy

170 gm thyroid with pseudopapillary
proliferation of columnar cells;
lymphoid nodules

2

PTU, 150 gm qid; propranolol,
40 mg qid

12

Bilateral subtotal
thyroidectomy

160 gm thyroid with similar histology
as in No. 1

3

PTU, 100 mg tid

10 mCi radioactive
iodine

—

5

*Typical of Craves' disease
PTU = propylthiouracil

Their low serum PBI and T4 values and the definitely
decreased 24-hour RAIU confirmed this diagnosis. However, as with most cases of hypothyroidism, the exact cause
was not apparent. Aside from patient 1, whose small goiter
occurred before the clinical findings of hypothyroidism
were evident, the other two patients did not show any clues
of "silent" or spontaneously resolving thyroiditis, subacute
thyroiditis (which usually leads to transient hypothyroidism
and, in rare instances, to permanent hypothyroidism), or of
Hashimoto's thyroiditis, which has been implicated as the
most frequent cause of this disorder. No patient had a
history of prior hyperthyroidism. While goiter in childhood
has been ascribed primarily to Hashimoto's thyroiditis (27),
the subsequent antithyroglobulin and antimicrosomal antibody titers in our patients did not confirm this impression,
although the relative insensitivity of the procedures employed might account for the negative results. The immunofluorescent procedure, which is more sensitive but less
specific for detecting thyroid antimicrosomal antibody, was
also negative in two subjects (28). Since these studies were
performed two to four years after the patients developed
myxedema, significant titers might have been present at an
earlier time. However, despite the development of significant thyromegaly and the presence of appropriate antigens
duringthe hyperthyrold phase, no anamnestic response in
terms of higher and significant antithyroglobulin and antimicrosomal antibody titers was observed. Furthermore,
since histological findings in two patients were not characteristic of Hashimoto's thyroiditis, it is doubtful that this
disorder accounts for the initial phase of hypothyroidism.
The possibility, however, of antibody-mediated TSH-receptor blockade as an initial event could not be ruled out.

subsequent menarche and normal menstrual periods after
thyroid hormone therapy in patient 1, the normal skull
x-rays of patients 2 and 3, and the appropriate changes in
the circulating levels of TSH in all three patients during
thionamide therapy, and subsequent surgery in the first two
subjects.
Immune-complex disease could also be implicated in the
evolution of this problem. Although circulating immune
complexes have been demonstrated for many thyroid disorders, their pathogenetic significance has not been made
clear except in glomerulonephritis (29,30).
The evolution of Graves' disease is clearly evident in all
patients. Classically, it consists of three components which
occur simultaneously or independently: hyperthyroidism,
infiltrative ophthalmopathy, and pretibial dermopathy (31).
Patients 1 and 2 presented with hyperthyroidism only. Their
physical findings, thyroid scans, and presence of LATS, a
type of thyroid-stimulating immunoglobulin (33), all suggested Graves' disease; histological findings bore this diagnosis out. In patient 3, Graves' disease presented with the
infiltrative ophthalmopathic component followed by the
hyperthyroid phase. Whether this was the ophthalmopathy
of Hashimoto's or of Graves' disease is a moot point, since
it has been described in both disorders (33,34). The negative Werner's suppression test during the patient's initial
euthyroid phase suggests the presence of a thyroid-stimulating immunoglobulin that caused a sufficient increase in
thyroid hormone levels to suppress TSH secretion. TSI
determinations, which could have confirmed this possibility, were not performed in this individual. However,
the elegant studies of Solomon, et al (35) indicate that in
euthyroid Graves' disease the relationship of thyroid-stimulating immunoglobulins to thyroid nonsuppressibility is
complex.

As an alternative mechanism for the development of hypothyroidism in these patients, TSH deficiency, with subsequent development of hyperthyroidism, has been described in one case study (7). However, several factors in
our three patients weaken these possible explanations: the

While the thyroid disorder in our three patients undoubtedly evolved from a hypothyroid to a hyperthyroid phase,
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we still do not understand the sequence of events. The
evolution of Hashimoto's thyroiditis to Graves' disease is
one consideration, which is supported by previous reports
of the concurrence of Graves' disease and Hashimoto's
thyroiditis in the same patient (32), the occurrence of these
disorders in identical twins (36-38) and in families (39), and
"Hashitoxicosis" (34,40). Our patients may represent a
variant of Hashimoto's t h y r o i d i t i s w i t h o u t the classic
serological and histological findings. Since both disorders
are considered to be autoimmune, the hypothesis of Voipe
(41) could be modified to explain this evolution. The defect
in immune surveillance (T-lymphocyte system), which
could be spontaneous, stress- or viral-induced, permits
organ-specific " J " lymphocytes to survive. They then interact with complementary antigen (thyroid gland, orbital
tissue, or pretibial skin in Graves' disease) to cause a cell-

mediated immune process in the target site. It is possible
that a cytotoxic, destructive process, probably mediated by
" J " or killer (K) lymphocytes directed at the thyroid gland,
led to initial hypothyroidism in our patients. Subsequently,
with continuing exposure of " B " lymphocytes to TSH
receptors on thyroid cell plasma membrane, specific thyr o i d - s t i m u l a t i n g i m m u n o g l o b u l i n s (TSI) were formed
(42-45), perhaps aided by "helper" T lymphocytes as well.
The presence of LATS, one type of TSI, in two patients,
lends credence to this hypothesis, since TSI could then lead
to a continuous stimulation of residual thyroid gland tissue
that would cause sufficient hyperplasia and growth to
account for the eventual hyperthyroid phase in our patients. However, for this situation to occur, the cytotoxic
component of this dual immune response must for some
reason fail so that the cytotrophic effect can prevail.
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